Is it weird to email someone after six months of silence?

Not if you have a new reason and you don't pretend the old thread is still warm. Lead with the trigger, remind them who you are in one line, and make the ask optional. Nostalgia without news is just another cold email with extra steps.

Is it okay to send this introduction on LinkedIn instead of email?

Yes if this CEO is actually active there and the thread isn't about long attachments. Keep the LinkedIn version even shorter. Don't paste the full email. One context line and one question is plenty. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

What should I never say in a Pharmaceuticals introduction?

Don't use consumer-startup slang. It's a credibility leak. A long origin story or a request to 'pick your brain.' Don't open with 'it's been a while' and then paste the old pitch. Those three mistakes show up constantly in Pharmaceuticals inboxes and they all read as "this was templated."

Can I use aggressive sales language in pharma outreach?

No. Unapproved claims, off-label hints, and fake urgency can create real problems. Be operational: timelines, review status, access, meeting logistics. Save clinical discussion for approved materials and the right role. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

How should a introduction to a Pharmaceuticals CEO change for long time no contact?

Fresh start. Don't scold them for the gap. Don't invent clinical claims. Don't treat HCPs like a funnel. If you don't know the rules, your email is a liability. The CEO is guarding time, reputation, and optionality, so the ask should stay at "one decision or a 10-minute yes, not a workshop." If you copy a generic template and only

Pharmaceuticals · CEO · Long Time No Contact

Introduction for Pharmaceuticals CEO: Long Time No Contact

When a Pharmaceuticals CEO goes quiet (long time no contact), the right introduction email does one job: make a reply cheaper than silence. They skim on a phone between meetings. If the first two lines don't name a business outcome, the rest never gets read. That's why this template leads with time through MLR, access, and compliant engagement rates instead

Last updated: 2026-09-02 · Reviewed by: Sales Email Template editors

We write templates the way we wrote emails on quota: short, specific, and easy to forward. When we cite research below, it is because the number changes how a buyer reads your note, not to pad the page.

Sources: HubSpot sales email benchmarks; Gong follow-up research

Why does this introduction work for a Pharmaceuticals CEO?

Make it easy to decline.
Speaks to follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick instead of a generic "value prop."
Fits how a CEO actually reads: Keep the whole note under 70 words unless they asked for detail.
Bring a new observation about their world, then offer a small, optional next step.
Lead with the overlap, not your résumé.

When should I send this to a Pharmaceuticals CEO?

If a mutual offered the intro, send it while their permission is fresh. Send when you have a real trigger: news, a useful artifact, a role change, a season. For this combo, treat "Only when you have a trigger" as the default, then adjust around launch calendars and review boards set speed. you don't. If you're emailing a CEO, Keep the whole note under 70 words unless they asked for detail.

What this CEO actually cares about

A CEO in Pharmaceuticals is protecting time, reputation, and optionality. They skim on a phone between meetings. If the first two lines don't name a business outcome, the rest never gets read. The hook that earns a look is a P&L, risk, or competitive issue they already feel. The ask should stay at this size: one decision or a 10-minute yes, not a workshop. Delete trigger: A long origin story or a request to 'pick your brain.' Tone: Direct, adult, light on process jargon. Talk like a peer who did the homework.

How Pharmaceuticals changes the note

Pharmaceuticals buyers are commercial, medical, and ops leads who work under review boards and long timelines. Don't invent clinical claims. Don't treat HCPs like a funnel. If you don't know the rules, your email is a liability. A credible proof point in this vertical sounds like: cut review cycles on a leave-behind by catching claims issues before legal saw the tenth draft. Watch the language. Words that land here include MLR, label, access, HCP, congress, promotional review. Launch calendars and review boards set speed. You don't. Words that work: MLR, label, access, HCP, congress, promotional review.

How should I customize this template before I send it?

Replace the pain line with an agency waiting on MLR while the sales team keeps asking 'is it approved yet'.
Keep the tone direct, adult, light on process jargon.
Don't attach your pitch deck to an intro.
Time it for Only when you have a trigger. Send when you have a real trigger: news, a useful artifact, a role change, a season.
Don't use consumer-startup slang. It's a credibility leak.

What mistakes should I avoid with this long time no contact note?

Giant bios make intros feel like homework.
Don't open with 'it's been a while' and then paste the old pitch.
Don't use consumer-startup slang. It's a credibility leak.
A long origin story or a request to 'pick your brain.'

How does this long time no contact scenario compare?

Dimension	For this template
Best send window	Only when you have a trigger
Ideal length	Keep the whole note under 70 words unless they asked for detail.
Primary ask	one decision or a 10-minute yes, not a workshop
Industry metric to cite	time through MLR, access, and compliant engagement rates
Tone	Direct, adult, light on process jargon. Talk like a peer who did the homework.
Unlike no response	This isn't a 4-day bump. It's a re-introduction with a new reason.
Unlike breakup	You're opening a door, not closing one. Still keep it easy to ignore.

What should I copy and send?

Copy-ready template

Subject

Quick intro on [shared problem]

Body

Hi [First Name],

I'm reaching out because [specific overlap], not because I collect new LinkedIn contacts.

In Pharmaceuticals, that usually shows up as follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick. Two reasons this might matter now: [trigger 1] and [trigger 2]. If I'm reading that wrong, tell me.

Re-earn a conversation, not restart a stale sequence at email 4.

If you'd rather I talk to [other role], I can do that.

Best,
[Your Name]
[Your Title]
[Your Company]

Questions people ask before they hit send

Use one sentence for who you help and one sentence for why now. Skip the origin story. If a mutual is involved, put their name near the top so the email has a human reason to exist. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

Related templates

Want a custom draft instead? Try the email generator.